Navigation Links
Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
Date:9/19/2013

m, Ventana has worked with more than 45 biopharmaceutical partners over the past decade and is currently engaged in over 150 collaborative projects to develop and commercialize companion diagnostics globally.

About Ventana Medical Systems, Inc.

Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.  VENTANA and the VENTANA logo are trademarks of Roche. Visit http://ventana.com/ to learn more.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: jacquie.bucher@ventana.roche.com

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates in 50 countries and more than 46,000 employees. Since it was founded in 1885, the family-ow
'/>"/>

SOURCE Ventana Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Life Technologies to Collaborate with Merck Serono for Companion Diagnostics Development and Commercialization
2. QB3 to Collaborate with Johnson & Johnson Innovation on New Incubator
3. Freeslate Collaborates with Medicines for Malaria Venture to Advance Therapeutic for Treating Malaria
4. DuPont Tate & Lyle Bio Products Collaborates with RML Incorporated to Develop Bio-Based Solution for Personal Care Products
5. Research Foundations Collaborate To Fund Phase 1 Study Of Cancer Drug In Alzheimers Disease Patients
6. Sigma Life Science and the Culture Collections of Public Health England Collaborate to Distribute Cells and Cellular Extracts
7. DuPont Collaborates with Agricultural Educators to Reach More Students
8. DuPont Pioneer and Mendel Biotechnology, Inc. Collaborate to Improve Water Use Efficiency and Photosynthesis in Corn
9. Lockheed Martin and Nanyang Technological University to collaborate on nanotechnology
10. Elsevier and Kanazawa University in Japan Collaborate to Map Universitys Research Performance
11. Ceres and Syngenta to Collaborate on Sweet Sorghum Market Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... -- RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") ... Symposium on Thymosins in Health and Disease in ... thymosin beta 4 (TB4) linked with rhodamine (a fluorescent ... a rodent model of stroke, it was visualized outside ... functional tissue of the brain).   The leakage of TB4 ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
(Date:10/22/2014)... Involution Studios , a healthcare ... new infographic, Understanding Ebola . The goal ... easy to follow informative tool for anyone wanting to ... and prevention. , "As the news has spread in ... outbreak represents not only a healthcare crisis with global ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
Breaking Biology Technology:Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5
... Medarex, Inc. (Nasdaq: MEDX ) announced today ... J.P. Morgan Healthcare Conference at 8:30 a.m. Pacific Time (11:30 ... will be webcast live and will be available in the ... . An archived edition of the presentation will be available ...
... PCYC ) today announced that in ... Associates ("RWD") made an unsecured loan to,Pharmacyclics, Inc. ... $5,000,000. As of,December 31, 2008, the company,s ... the $5,000,000 in loan proceeds. RWD,is controlled ...
... Jan. 6 Omeros Corporation today announced that The ... grant against milestones to support the Company,s collaboration with ... a new target for the treatment of Parkinson,s disease. ... disease, Omeros is the first to link its novel ...
Cached Biology Technology:Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Pharmacyclics Secures $5.0 Million in Debt Financing 2Pharmacyclics Secures $5.0 Million in Debt Financing 3Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 2Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 3
(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
(Date:10/16/2014)... Researchers at William and Mary,s Virginia Institute of ... from the Environmental Protection Agency to identify the ... and to develop tools to help local governments ... project depends critically on a dataset of tidal-marsh ... 1970s. Only with this historical baseline can today,s ...
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... infectious diseases are urgently needed in resource-limited countries. ... Academy of Microbiology colloquium, "Bringing the Lab to ... Settings," describes the challenges inherent in bringing new ... the world where they are needed most. Point-of-care ...
... team of UC Davis investigators has found that a genetic ... prostate cancer. The mutation of the so-called p53 (or Tp53) ... now has never been shown to act as an initiating ... treating the disease. The study was published online ...
... one of the few probiotics with medical food designation for ... of more than 80 studies that have demonstrated its use ... ileal pouch. Ulcerative colitis patients, in particular, have been shown ... drug regimen. One particular study shows that the combination of ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer 2By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates 2
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Human Cell Line Slides...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Mouse Cell Line Slides...
Biology Products: